检索结果-南通市图书馆

Doxorubicin-Ioaded Fe3O4@MoS2-PEG-2DG nanocubes as a theranostic platform for magnetic resonance imaging- guided chemo-photothermal therapy of breast cancer

引用

Nano Research 2018年第5期11卷 2470-2487页

作者： Wensheng Xie Qin Gao Dan Wang Zhenhu Guo Fei Gao Xiumei Wang Qiang Cai Si-shen Feng Haiming Fan Xiaodan Sun Lingyun Zhao State Key Laboratory of New Ceramics and Fine Processing School of Materials Science & Engineering Tsinghua University Beijing 100084 China Key Laboratory of Advanced Materials Ministry of Education of China School of Materials Science & Engineering Tsinghua University Beijing 100084 China School of Chemical and Biomolecular Engineering Notional University of Singapore 119077 Singapore College of Chemistry and Materials Science Northwest University Xi'an 710069 China

Molybdenum disulfide （MoS2）, a typical transition-metal dichalcogenide, has attracted increasing attention in the field of nanomedicine because of its preeminent properties. In this study, magnetic resonance imaging （MRI）-guided chemo-photothermal therapy of human breast cancer xenograft in nude mice was demonstrated using a novel core/shell structure of Fe3O4@MoS2 nanocubes （IOMS NCs） via the integration of MoS2 （MS） film onto iron oxide （IO） nanocubes through a facile hydrothermal method. After the necessary PEGylation modification of the NCs for long-circulation purposes, such PEGylated NCs were further capped by 2-deoxy-D-glucose （2-DG）, a non-metabolizable glucose analogue to increase the accumulation of the as-prepared NCs at the tumor site, as 2-DG molecules could be particularly attractive to resource-hungry cancer cells. Such 2-DG- modified PEGylated NCs （IOMS-PEG-2DG NCs） acted as drug-carriers for doxorubicin （DOX）, which could be easily loaded within the NCs. The obtained IOMS-PEG（DOX）-2DG NCs exhibited a 3？2 relaxivity coefficient of 48.86 （mM）^-1·s^-1 and excellent photothermal performance. 24 h after intravenous injection of IOMS-PEG（DOX）-2DG NCs, the tumor site was clearly detected by enhanced T2-weighted MRI signal. Upon exposure to an NIR 808-nm laser for 5 rain at a low power density of 0.5 W·cm^-2 a marked temperature increase was noticed within the tumor site, and the tumor growth was efficiently inhibited by the chemo-photothermal effect. Therefore, our study highlights an excellent theranostic platform with great potential for targeted MRI-guided precise chemo-photothermal therapy of breast cancer.

关键词： iron oxide nanocubes molybdenum disulfide multimodality therapy photothermal therapy nanotheranostics

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy:A retrospective study

引用

World Journal of Gastroenterology 2022年第15期28卷 1574-1587页

作者： Zi-Bo Yuan Hong-Bo Fang Quan-Kai Feng Tao Li Jie Li Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina Henan Research Centre for Organ Transplantation the First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052Henan ProvinceChina

BACKGROUND Intrahepatic cholangiocarcinoma(ICC)is a highly malignant *** is an effective treatment for early ICC,but postoperative recurrence greatly affects patient *** on recurrent ICC after hepatectomy are *** To investigate the clinical characteristics of patients with recurrent ICC after hepatectomy,analyse prognostic factors and explore diagnosis and treatment *** A retrospective analysis was performed on all ICC patients undergoing hepatectomy from January 2013 to August *** with postoperative recurrence were selected according to the inclusion and exclusion *** overall survival was plotted by the Kaplan-Meier method,and differences were assessed by univariate survival analysis using the log-rank *** analysis of cumulative survival was performed using the Cox proportional risk *** During the 8-year study period,103 patients underwent ICC-related hepatectomy,and 54 exhibited postoperative *** median disease-free survival(DFS)was 6 mo,the median overall survival(OS)was 9 mo,and the cumulative OS rates at 1,2 and 3 years after the operation were 40.7%,14.8%and 7.4%,*** median OS after recurrence was 4 mo,and the cumulative OS rates at 1,2 and 3 years after recurrence were 16.1%,6.7%and 3.4%,*** analysis showed that alcohol consumption[hazard ratio(HR)=4.64,95%confidence interval(CI):1.53-14.04,P=0.007]and DFSmultimodality therapy after recurrence of ICC was 7 mo,which was significantly higher than that of patients receiving only local therapy(3 mo),patients receiving systematic therapy(4 mo)and patients receiving the best supportive therapy(1 mo).Patients

关键词： Intrahepatic cholangiocarcinoma Hepatectomy Recurrence multimodality therapy Prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Further understanding of an uncommon disease of combined small cell lung cancer： clinical features and prognostic factors of 114 cases

引用

Chinese Journal of Cancer Research 2016年第5期28卷 486-494页

作者： Yu Men Zhouguang Hui Jun Liang Qinfu Feng Dongfu Chen Hongxing Zhang Zefen Xiao Zongmei Zhou Weibo Yin Luhua Wang Department of Radiation Oncology national cancer center/Cancer Institute & Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021China Department of Special Medical Services & department of radiation oncology national cancer center/Cancer Institute & Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100021China

Objective： Combined small cell lung cancer （C-SCLC） is an uncommon subgroup of small cell lung cancer （SCLC） and few clinical data can be referred. Our study is to investigate the clinical features and prognostic factors of C-SCLC, as well as the role of multimodality ***： Between January 2004 and December 2012, patients with histologically diagnosed C-SCLC were retrospectively analyzed. The survivals were evaluated with the Kaplan-Meier method. Univariate and multivariate analyses were used to evaluate potential prognostic ***： One hundred and fourteen patients were enrolled, with a median age of 59 （range： 20-79） years old. The most common combined component was squamous cell carcinoma （52.6%）. Among these patients, the disease was stage I, II, III and IV in 9.6%, 19.3%, 46.5% and 24.6% of the patients, respectively. Eighty patients （70.2%） received at least two of the three modalities containing chemotherapy, radiotherapy and surgery. The median follow-up was 32.5 months. The median time of overall survival （OS） was 26.2 months. On univariate analysis, smoking （P=0.029）, Karnofsky performance score （KPS）〈80 （P=0.000）, advanced TNM stage （P=0.000）, no surgery （P=0.010）, positive resection margin （P=0.000）, positive lymph nodes ≥4 （P=0.000）, positive lymph node ratio 〉10% （P=0.000） and non-multimodality treatment （P=0.004） were associated with poor OS. Multivariate analysis confirmed that smoking, advanced TNM stage, positive resection margin and positive lymph nodes ratio 〉 10% were poor prognostic features. Conclusions： C-SCLC has a relatively early stage and good prognosis, which may due to the underestimated diagnosis in non-surgical patients. multimodality therapy is recommended, especially for limited disease. Smoking, advanced TNM stage, positive resection margin and positive lymph nodes ratio 〉10% are poor prognostic factors.

关键词： Combined small cell lung carcinoma diagnosis prognosis multimodality therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

multimodality management for chronic subdural hematoma in China: protocol and characteristics of an ambidirectional, nationwide, multicenter registry study

引用

中华神经外科杂志(英文) 2024年第2期10卷 1页

作者： Liu Tao Zhao Zhihao Huang Jinhao Zhu Xide Chen Weiliang Lin Kun Yu Yunhu Li Zhanying Fan Yibing Liu Mingqi Nie Meng Liu Xuanhui Gao Chuang Quan Wei Qian Yu Wu Chenrui Yuan Jiangyuan Wu Di Lv Chuanxiang Dong Shiying Mi Liang Tian Yu Tian Ye Zhang Jianning Jiang Rongcai Department of Neurosurgery Tianjin Medical University General Hospital Tianjin China Ministry of Education Tianjin Neurological Institute Key Laboratory of Post Neuro-injury Neuro-repair and Regeneration in Central Nervous System Tianjin Medical University General Hospital Tianjin China Department of Neurosurgery Linyi People’s Hospital Shandong China Department of Neurosurgery Haining People’s Hospital Zhejiang China Department of Neurosurgery Fujian Provincial Hospital Fujian China Department of Clinical Research Center for Neurological Disease the People’s Hospital of HongHuaGang District of ZunYi Guizhou China Department of Neurosurgery Kailuan General Hospital Hebei China Department of Neurosurgery Tianjin First Central Hospital Tianjin China Department of Neurosurgery The First Hospital of Jilin University Changchun China

Background Despite its prevalence, there is ongoing debate regarding the optimal management strategy for chronic subdural hematoma (CSDH), reflecting the variability in clinical presentation and treatment outcomes. This ambidirectional, nationwide, multicenter registry study aims to assess the efficacy and safety of multimodality treatment approaches for CSDH in the Chinese ***/design A multicenter cohort of CSDH patients from 59 participating hospitals in mainland China was enrolled in this study. The treatment modalities encompassed a range of options and baseline demographics, clinical characteristics, radiographic findings, and surgical techniques were documented. Clinical outcomes, including hematoma resolution, recurrence rates, neurological status, and complications, were assessed at regular intervals during treatment, 3 months, 6 months, 1 year, and 2 years *** Between March 2022 and August 2023, a comprehensive cohort comprising 2173 individuals who met the criterion was assembled across 59 participating clinical sites. Of those patients, 81.1% were male, exhibiting an average age of 70.12 ± 14.53 years. A historical record of trauma was documented in 48.0% of cases, while headache constituted the predominant clinical presentation in 58.1% of patients. The foremost surgical modality employed was the burr hole (61.3%), with conservative management accounting for 25.6% of cases. Notably, a favorable clinical prognosis was observed in 88.9% of CSDH patients at 3 months, and the recurrence rate was found to be 2.4%.Conclusion This registry study provides critical insights into the multimodality treatment of CSDH in China, offering a foundation for advancing clinical practices, optimizing patient management, and ultimately, improving the quality of life for individuals suffering from this challenging neurosurgical *** registration ChiCTR2200057179

关键词： Chronic subdural hematoma multimodality therapy Outcome Recurrence

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Brain Metastases in Patients with Gynecologic Cancers: A Single Institution Experience and Review of the Literature

引用

Open Journal of Obstetrics and Gynecology 2016年第9期6卷 544-552页

作者： Madiha A. Gilani Noelle L. Williams Carolyn Giordano Norman Rosenblum Wenyin Shi Pramila Anne Russell J. Schilder Thomas Jefferson University Hospital Philadelphia PA USA Department of Radiation Oncology Sidney Kimmel Cancer Center Thomas Jefferson University Hospital Philadelphia PA USA Office of Institutional Research Thomas Jefferson University Philadelphia PA USA Sidney Kimmel Cancer Center Thomas Jefferson University Hospital Philadelphia PA USA

Objective: Brain Metastasis (BM) from primary gynecologic cancers is a rare entity. The advances and successes in the treatment of primary gynecologic malignancies, have led to prolonged survival and, a higher incidence of BM. This study aims to report the experience at our institution in managing these patients, and provide possible data points that may be essential to note as prognostic factors, and see if our findings are consistent with the literature in this subject. We also aim to provide a brief literature review of patients with gynecologic cancers and BM. Methods: This is a small single institution retrospective study of 23 patients with a gynecologic malignancy and BM, identified between the years 2007-2015. Data were collected on variables including patient demographics, disease and treatment. Results: The median overall survival from the primary diagnosis was 28 months. Median time from diagnosis of BM to death was 9 months. Conclusion: The outcomes in our study are similar to what is stated in the current literature with regard to BM from gynecologic malignancies. Our literature search also revealed that the molecular analysis and treatment of the primary tumor remain important to prevent BMs. The tendency of tumors to metastasize varies for one tumor type to another for the same type of tumor. The tendency to develop BM may not only depend on risk factors such as stage, grade, and histology, but also on the genetic profile of the primary tumor. The study suggests that multimodal treatment of BM has better outcomes in managing BM from gynecologic cancers.

关键词： Gynecologic Malignancies Brain Metastasis Prognostic Factors multimodality therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Prediction of Response to multimodality Treatment inEsophageal Cancer

引用

The Chinese-German Journal of Clinical Oncology 2004年第4期3卷 253-256页

作者： RalfMetzger HuanXi FutoshiMiyazono HiroshiHigashi UteWarnecke-Eberz StephanE.Baldus JanBrabender PaulM.Schneider DepartmentofVisceral-andVascularSurgery UniversityofCologneCologneGermany DepartmentofGeneralSurgery BeijingHospitalBeijingChina FirstDepartmentofSurgery UniversityofKagoshimaSchoolofMedicineKagoshimaJapan InstituteofPathology UniversityofCologneCologneGermany

Patients with locally advanced esophageal cancer have a dismal prognosis when treated exclu- sively by surgery. This fact prompted many investigators to apply neoadjuvant treatment strategies in an e?ort to improve survival. Results from phase III randomized trials are encouraging however, they revealed 五笔字型计算机汉字输入技术 that only patients with major histopathological response will bene?t from treatment. Therefore, predic- tive molecular markers indicating response or non-response to neoadjuvant treatment would be extremely helpful in selecting patients for current and future treatment protocols. In this paper we review the role of the molecular markers ERCC1 (excision repair cross-complementing 1 gene) and c-erbB-2 (synonym: HER2/neu) in predicting response to radiochemotherapy and outcome for patients with locally advanced resectable esophageal cancers (cT2-4, Nx, M0). The results are promising and it appears that we might expect to unequivocally identify with ERCC1 and c-erbB-2 respectively, approximately up to one third of patients who ful?l the criteria for neoadjuvant treatment for locally advanced esophageal cancer but will not bene?t from our treatment protocol. Integration of such markers in the clinical setting might prevent a substantial number of patients from expensive, non-e?ective and potentially harmful therapies, and could lead to a more individualized type of combined multimodality treatment in the near future.

关键词： esophageal cancer response prediction multimodality therapy neoadjuvant radiochemotherapy ERCC1 c-erbB-2

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Clinical analysis of long-term survivors for unresectable hepatocellular carcinoma

引用

The Chinese-German Journal of Clinical Oncology 2010年第3期9卷 161-164页

作者： Baihong Zhang Xianghui Wang Hongyun Yue Changquan Ling Department of Oncology General Hospital of People＇s Liberation Army Lanzhou 730050 China Department of Ophthalmology General Hospital of People＇s Liberation Army Lanzhou 730050 China Department of Traditional Chinese Medicine Changhai Hospital Second Military Medical University Shanghai 200433 China

Objective:The objectives of this study were to evaluate the long-term results with multimodality therapy, and to clarify the clinicopathologic of features of patients surviving ≥ 3 years for unresectable hepatocellular carcinoma(HCC).Methods:Between 1999 and 2003, a total of 166 patients underwent multimodality therapy for unresectable *** patients underwent multimodality therapy, such as transarterial chemoembolization(TACE), chemotherapy, local ablative therapy, and/ or Chinese traditional ***-nine(23.5%) patients survival ≥ 1 years, and 10(6.0%) patients survived ≥ 3 *** 39 patients surviving over 1 year were investigated in this *** clinical and biologic variables were assessed using univariate and multivariate ***:TNM staging and tumor extension were isolated by univariate *** tumor extension was independent risk factors by multiple regression *** these, 25.6%(10 of 39) survived over 3 *** 10 patients surviving over 3 years were investigated *** the end of June 2004, follow-up varied from 3 years and 2 months to 5 years and 1 *** patients were still alive with free of ***:Tumor extension was demonstrated to be prognostic of long-term *** therapy may make a major contribution to achieving long-term survival in patients with unresectable HCC.

关键词： hepatocellular carcinoma survival prognostic features multimodality therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：